

**The Enroll-HD Clinical Trial Committee (CTC) provides recommendations and guidance to clinical trial sponsors for clinical development and/or review of trial protocols for operational support using Enroll-HD resources**

- Coordinates the initial contact point for sponsors planning interventional therapeutic HD clinical programs
- Offers expert advice to partners in pharma, biotech, device companies and academic consortia.
- Access to CHDI clinical expertise
- Panel of independent expert advisors in HD and all aspects of clinical trial design and methodology
- Interface between the Enroll-HD platform and partners
- Provision of advice and platform support and provides an opportunity for consultation in the early stages of protocol/program development
- Oversight of HD Clinical Trial Site Certification Program



Chair: Cristina Sampaio; Management: Juliana Bronzova, David Howland, Tim McLean, Swati Sathe, Jenny Townhill



## Enroll-HD Clinical Trial Committee (CTC): Support for Clinical Development of HD Therapeutics



The Enroll-HD Platform Team



**HD Clinical Trial Site Certification Program**

Informs Enroll-HD platform support for site feasibility and identification

Open to all HD clinical sites worldwide: assesses fundamental criteria for HD clinical trial participation

- HD patient population
- Site staff expertise and training (e.g. GCP, HD rating scales)
- Facilities

**138 clinical trial ready certified sites**

To learn more and initiate discussions contact us [Jenny.Townhill@Enroll-HD.org](mailto:Jenny.Townhill@Enroll-HD.org)

Enroll-HD is funded by the CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for HD.